Trials / Unknown
UnknownNCT05884801
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of QLS1103 in Subjects With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 148 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS1103 | Oral dose |
Timeline
- Start date
- 2023-06-30
- Primary completion
- 2025-01-30
- Completion
- 2025-07-30
- First posted
- 2023-06-01
- Last updated
- 2023-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05884801. Inclusion in this directory is not an endorsement.